allantoin has been researched along with Chronic Kidney Diseases in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pruritus is the most common skin symptom in patients with CKD, especially in end-stage renal disease." | 5.91 | Allantoin induces pruritus by activating MrgprD in chronic kidney disease. ( Dong, X; Jing, T; Jun, S; Shen, X; Sheng, M; Sun, J; Sun, Y; Tang, Z; Wang, C; Yang, Y; Yu, G; Zhu, C, 2023) |
| "Amelioration of both oxidative and inflammation status after cholesterol lowering treatment in CKD might be mediated by restoration of antioxidant taurine concentrations during therapy (from 51." | 5.20 | Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. ( Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A, 2015) |
| " Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)." | 3.83 | Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016) |
| "Pruritus is the most common skin symptom in patients with CKD, especially in end-stage renal disease." | 1.91 | Allantoin induces pruritus by activating MrgprD in chronic kidney disease. ( Dong, X; Jing, T; Jun, S; Shen, X; Sheng, M; Sun, J; Sun, Y; Tang, Z; Wang, C; Yang, Y; Yu, G; Zhu, C, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 1 |
| Sun, Y | 1 |
| Zhu, C | 1 |
| Shen, X | 1 |
| Sun, J | 1 |
| Jing, T | 1 |
| Jun, S | 1 |
| Wang, C | 1 |
| Yu, G | 1 |
| Dong, X | 1 |
| Sheng, M | 1 |
| Tang, Z | 1 |
| Zinellu, A | 4 |
| Sotgia, S | 4 |
| Sotgiu, E | 2 |
| Assaretti, S | 1 |
| Baralla, A | 1 |
| Mangoni, AA | 3 |
| Satta, AE | 4 |
| Carru, C | 4 |
| Hu, JR | 1 |
| Coresh, J | 1 |
| Inker, LA | 1 |
| Levey, AS | 1 |
| Zheng, Z | 1 |
| Rebholz, CM | 1 |
| Tin, A | 1 |
| Appel, LJ | 1 |
| Chen, J | 1 |
| Sarnak, MJ | 1 |
| Grams, ME | 1 |
| Sanna, M | 1 |
| Ena, S | 1 |
| Pisanu, E | 1 |
| Loriga, G | 1 |
| Deiana, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy[NCT00861731] | Phase 4 | 30 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for allantoin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients.
Topics: 5-Methylcytosine; Aged; Allantoin; Biomarkers; Cholesterol; DNA Methylation; Down-Regulation; Ezetim | 2017 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Res | 2015 |
LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
Topics: Allantoin; Apolipoproteins B; Azetidines; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Ezetim | 2012 |
3 other studies available for allantoin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Allantoin induces pruritus by activating MrgprD in chronic kidney disease.
Topics: Allantoin; Animals; Calcium; Mice; Pruritus; Receptors, G-Protein-Coupled; Renal Insufficiency, Chro | 2023 |
Serum metabolites are associated with all-cause mortality in chronic kidney disease.
Topics: Adult; Aged; Allantoin; Biomarkers; Cause of Death; Cohort Studies; Female; Follow-Up Studies; Fumar | 2018 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema | 2016 |